Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Gains from Investment Securities (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Gains from Investment Securities for 8 consecutive years, with $152000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gains from Investment Securities fell 31.84% year-over-year to $152000.0, compared with a TTM value of -$548000.0 through Sep 2025, down 219.65%, and an annual FY2022 reading of $12000.0, down 99.11% over the prior year.
  • Gains from Investment Securities was $152000.0 for Q3 2025 at X4 Pharmaceuticals, up from -$369000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $1.3 million in Q4 2021 and bottomed at -$504000.0 in Q4 2024.
  • Average Gains from Investment Securities over 5 years is $87400.0, with a median of $51000.0 recorded in 2023.
  • The sharpest move saw Gains from Investment Securities surged 713.24% in 2021, then plummeted 995.65% in 2024.
  • Year by year, Gains from Investment Securities stood at $1.3 million in 2021, then tumbled by 99.11% to $12000.0 in 2022, then crashed by 483.33% to -$46000.0 in 2023, then tumbled by 995.65% to -$504000.0 in 2024, then skyrocketed by 130.16% to $152000.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for XFOR at $152000.0 in Q3 2025, -$369000.0 in Q2 2025, and $173000.0 in Q1 2025.